Eric Schadt

Eric Schadt

Formal First Name

Eric Schadt is the Founder, President and Chief Research & Development Officer at Sema4, a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. In his roles, Eric is responsible for leading Sema4's data and informatics, science, and medical functions, advancing its genomic testing solutions and further evolving its information platform for use in pharma and health system partnerships. He is a world-renowned expert on clinical medicine, with over 20 years of experience building groups and companies to reduce the complexity of human diseases. His research has provided novel insights into what is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena. Eric is also the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health and Computational Biology at Icahn School of Medicine at Mount Sinai.

Professional Experience

Academic History


  • Now, with Centrellis®, Sema4’s innovative health intelligence platform, Eric is using advanced network analysis to build better models of human health and deliver personalized insights for patients.

  • As CEO, he oversaw rapid growth, driven by the company’s dedication to advancing healthcare through data-driven insights.

  • He presided over Sema4 as it became a public company trading on Nasdaq in July 2021.


  • He was previously Founding Director of Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences.

  • His lab and broader efforts at the Icahn Institute focus on the integration of diverse, very large scale data to build predictive models of disease that can aid in providing more accurate diagnoses of disease and how best to treat it.

  • He has published more than 500 peer-reviewed papers in leading scientific journals and contributed to discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease.

  • He is a Co-founder and Board Member of Sage Bionetworks, a nonprofit biomedical research and technology development organization.

  • He was Chief Scientific Officer at Pacific Biosciences, and a former Exec. Director for Merck, where he led genetics, systems biology, and other integrative biology efforts.

  • He served as Chief Scientist at Rosetta Inpharmatics, and Senior Research Scientist for Roche Bioscience.